4CPS-128 Effectiveness of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

BackgroundAbiraterone acetate (AA) and enzalutamide are authorised oral therapies in the treatment of metastatic castration-resistant prostate cancer (mCRPC), which act by inhibiting androgen synthesis.PurposeTo compare the effectiveness of AA and enzalutamide in patients with mCRPC.Material and met...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of hospital pharmacy. Science and practice 2018-03, Vol.25 (Suppl 1), p.A101-A101
Hauptverfasser:	García, AM Sánchez, Mateos, A Andújar, Esquerdo, M Llinares, Irigaray, L Soriano, Torres, R Antón, Ruiz, A Navarro
Format:	Artikel
Sprache:	eng
Schlagworte:	Metastasis Prostate cancer Section 4: Clinical pharmacy services
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!